Get the Stockscreener App
65.73
9.31%
5.60
After Hours:
65.73
Korro Bio Inc stock is traded at $65.73, with a volume of 61,087.
It is up +9.31% in the last 24 hours and up +95.68% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$60.13
Open:
$61.11
24h Volume:
61,087
Relative Volume:
0.59
Market Cap:
$577.64M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-82.84M
1W Performance:
+3.95%
1M Performance:
+95.68%
6M Performance:
+12.86%
1Y Performance:
+0.00%
1-Day Range:
$60.08
$66.01
1-Week Range:
$55.10
$66.01
52-Week Range:
$30.00
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
ONE KENDALL SQUARE. BUILDING 600-700, CAMBRIDGE
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio (NASDAQ:KRRO) Shares Gap DownShould You Sell? - MarketBeat
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - The Manila Times
Korro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATD - Marketscreener.com
Korro Bio (NASDAQ:KRRO) Trading Down 5.1%Time to Sell? - MarketBeat
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap - Investing.com India
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap By Investing.com - Investing.com South Africa
Korro Bio (NASDAQ:KRRO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Korro Bio (NASDAQ:KRRO) Coverage Initiated at Raymond James - Defense World
RBC lifts Korro Bio stock target on positive RNA editing outlook - Investing.com Australia
Raymond James Initiates Coverage of Korro Bio (KRRO) with Strong Buy Recommendation - MSN
Korro Bio price target raised to $105 from $95 at RBC Capital - TipRanks
RBC lifts Korro Bio stock target on positive RNA editing outlook By Investing.com - Investing.com South Africa
Royal Bank of Canada Boosts Korro Bio (NASDAQ:KRRO) Price Target to $105.00 - MarketBeat
Korro Bio initiated with a Strong Buy at Raymond James - TipRanks
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Korro bio CFO Vineet Agarwal sells $799,526 in stock - Investing.com India
Insider Selling: Korro Bio, Inc. (NASDAQ:KRRO) CFO Sells 10,216 Shares of Stock - MarketBeat
Korro bio CFO Vineet Agarwal sells $799,526 in stock By Investing.com - Investing.com Australia
Korro Bio shares target lifted, buy rating on RNA editing potential - Investing.com
Korro Bio (NASDAQ:KRRO) Trading Down 4.1%Should You Sell? - MarketBeat
HC Wainwright Increases Korro Bio (NASDAQ:KRRO) Price Target to $115.00 - MarketBeat
Korro Bio price target raised to $115 from $100 at H.C. Wainwright - TipRanks
BMO maintains steady target on Korro Bio shares By Investing.com - Investing.com Australia
500: Something went wrong - Investing.com
180 Life Sciences, Korro Bio, NuScale Power: Retail Investors Turn Most Bullish On These Stocks - Barchart
BMO maintains steady target on Korro Bio shares - Investing.com India
What is KRRO’s price-to-sales ratio telling us about the company’s value? - US Post News
Korro Bio (NASDAQ:KRRO) Shares Gap UpTime to Buy? - MarketBeat
Wall Street Analysts Think Korro Bio, Inc. (KRRO) Could Surge 239.54%: Read This Before Placing a Bet - Yahoo Finance UK
RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data - Bloomberg
Millennium Management LLC Purchases 23,307 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Down 11.9% in September - MarketBeat
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times
Point72 Asset Management L.P. Raises Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
NEA Management Company LLC Boosts Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
19,148 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Bought by Bank of New York Mellon Corp - MarketBeat
19,148 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Purchased by Bank of New York Mellon Corp - Defense World
Tri Locum Partners LP Takes Position in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Brown Brothers Harriman & Co. Acquires Shares of 813 Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Stock Surge: Corcept Therapeutics Inc (CORT) Closes at 40.92, Marking a -3.19 Increase/Decrease - The Dwinnex
Korro Bio, Inc. Forecasted to Post Q3 2024 Earnings of ($2.79) Per Share (NASDAQ:KRRO) - MarketBeat
Korro Bio (NASDAQ:KRRO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Korro Bio (NASDAQ:KRRO) Given “Outperform” Rating at Royal Bank of Canada - Defense World
Novo Nordisk and Korro Bio Take RNA Editing to Cardiometabolic Diseases - Inside Precision Medicine
Korvest Ltd Director Buys First Shares - TipRanks
Korro Bio - The Pharma Letter
ORGN stock touches 52-week high at $1.73 amid market optimism - Investing.com Australia
Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agarwal Vineet | Chief Financial Officer |
Oct 17 '24 |
Sale |
78.26 |
10,216 |
799,527 |
0 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):